Discontinued — last reported Q4 '20
Pfizer Net Cash Collateral Posted - Derivative Instruments increased by 9.1% to $1.20B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 30.9%, from $917.00M to $1.20B. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase indicates higher liquidity usage for margin requirements, which may constrain free cash flow during periods of market stress.
This metric represents the net amount of cash collateral the firm has posted to counterparties to support its derivative...
Standard metric for assessing the liquidity impact of derivative trading activities at major investment banks.
net_cash_collateral_posted_derivatives| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $716.00M | $357.00M | $526.00M | $414.00M | $612.00M | $831.00M | $867.00M | $1.00B | $767.00M | $764.00M | $917.00M | $640.00M | $1.10B | $1.20B |
| QoQ Change | — | -50.1% | +47.3% | -21.3% | +47.8% | +35.8% | +4.3% | +15.3% | -23.3% | -0.4% | +20.0% | -30.2% | +71.9% | +9.1% |
| YoY Change | — | — | — | -42.2% | +71.4% | +58.0% | +109.4% | +63.4% | -7.7% | -11.9% | -8.3% | -16.6% | +44.0% | +30.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.